Levonorgestrel-Releasing Intrauterine System as a Contraceptive Method in Nulliparous Women: A Systematic Review

Magdalena Zgliczynska 1, Karol Kocaj 2, Iwona Szymusik 3, Magdalena Maria Dutsch-Wicherek 4, Michal Ciebiera 1, * and Katarzyna Kosinska-Kaczynska 1

1 2nd Department of Obstetrics and Gynecology, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland; zgliczynska.magda@gmail.com (M.Z.); katarzyna.kosinska-kaczynska@cmkp.edu.pl (K.K.-K.)
2 Medical University of Silesia, 40-055 Katowice, Poland; kocajkarol.kk@gmail.com
3 1st Department of Obstetrics and Gynecology, Medical University of Warsaw, 02-015 Warsaw, Poland; iwona.szymusik@gmail.com
4 Department of Psychiatry, Centre of Postgraduate Medical Education, 01-809 Warsaw, Poland; dutsch.wicherek@gmail.com
* Correspondence: michal.ciebiera@gmail.com; Tel.: + 48-22-5690274

Received: 29 April 2020; Accepted: 29 June 2020; Published: 3 July 2020

Abstract: The aim of this review was to summarize the available evidence about the use of levonorgestrel-releasing intrauterine system (LNG-IUS) as a contraceptive method in nulliparous women. For this purpose, studies evaluating the efficacy, safety, bleeding pattern, satisfaction and discontinuation of the levonorgestrel-releasing intrauterine system in nulliparous women were analyzed. Only original research articles published in English between 1990–27th March 2020 were considered eligible. Reviews, book chapters, case studies, conference papers, opinions, editorials and letters were excluded. The systematic literature search of PubMed/MEDLINE, Scopus, Embase and Cochrane Library databases identified 816 articles, 23 of which were analyzed. The available evidence indicates that LNG-IUS is an effective and safe contraceptive method for nulliparous women that achieves high levels of satisfaction among patients. Moreover, nulliparous women seem to experience fewer expulsions than parous ones. Bleeding pattern is acceptable for the majority of patients, and bleeding disorders mainly occur in the first months after the insertion. More in-depth, long-term prospective studies are needed in this patient group to determine risk factors for the occurrence of side effects and associated discontinuations, which should not, however, delay the wider use of the method in this group, given the number of advantages.

Keywords: contraception; intrauterine device; intrauterine system; levonorgestrel-releasing intrauterine system; nulliparous; nulliparity

1. Introduction

Contraception (or birth control) is a deliberate use of methods or devices to prevent pregnancy as a consequence of sexual intercourse. Birth control has been used since ancient times, but its efficacy and safety has always been a problematic matter. A great progress in contraception research was observed in the 20th century, when contraceptives improved women’s quality of life (QoL) and reduced various health conditions related to unplanned pregnancies [1,2]. Due to this revolution, couples may currently have sexual intercourse at any desired time [3].

Intrauterine devices are a form of long-acting reversible contraception (LARC) methods. They are placed in a woman’s uterus. The new era of hormonal intrauterine devices (IUD) started when Luukkainen (1976) replaced the IUD copper filament with a small reservoir releasing constant daily...
doses of levonorgestrel [4]. Most of its contraceptive effect results from the hormonally-induced endometrial atrophy, and from the physicochemical changes of the cervical mucus [4]. Nowadays, hormonal IUDs are believed to result in one of the greatest satisfaction among users [5,6]. According to Canadian Contraception Consensus, LARCs are the most effective reversible contraceptive methods and have the highest continuation rates [7–9]. The numbers are satisfying—0.2% of women (both multiparous and nulliparous) using hormonal IUDs experience an unintended pregnancy within the first year of using this method [10]. Beyond its high efficacy, it offers a variety of potential non-contraceptive therapeutic benefits, e.g., it contributes to partial or complete menstrual suppression, improvement in dysmenorrhea and amelioration in pain associated with endometriosis and adenomyosis [11]. In addition to the aforementioned short-term effects, it also reduces the lifetime risk of endometrial cancer and ovarian cancer [12].

Most gynecological societies support the use of hormonal IUDs, e.g., the American College of Obstetricians and Gynecologists (ACOG) has stated in their guidelines that LARCs are a safe and acceptable means of LARC for both adults and adolescents, as well as parous and nulliparous women [13]. In most situations the advantages seem to outweigh the potential risks. According to available data, the use of LARCs in the United States (including hormonal IUDs) increased almost three times from 2009 (2.1%) to 2012 (5.9%) [14]. As stated by Lohr et al., IUDs should be routinely included in the contraception options offered to the majority of women, including those who did not give birth [15]. Even with many positive expert opinions and studies conducted in large groups, hormonal IUDs still trigger a lot of skepticism [16]. As found in study by Madden et al., only 31% of contraception providers consider an IUD appropriate for adolescents and young women [17]. In a different study, Luchowski et al. found that only two thirds of gynecologists considered IUDs appropriate for nulliparous women [18]. Moreover, numerous young women seem to have limited awareness and information about IUDs [19,20]. According to the Contraceptive CHOICE Project and other similar studies, more than half of adolescent patients preferred LARC methods over non-LARC ones after being properly advised and taught about contraceptive methods and their potential advantages and disadvantages [20,21]. Therefore, unlimited access to reliable sources of information is crucial.

To this day, several systematic reviews on the use of IUD in adolescents and nulliparous women have been conducted. Among those published in the recent years, the main topic became the IUD insertion procedure and pain management in this specific population [22–24]. They indicated higher rates of difficulties in insertion, insertion failure and pain during insertion in nulliparous, but at the same time, highlight the existence of potentially helpful interventions, such as cervix preparation with the use of misoprostol or lidocaine anesthesia [22–24]. Other available summaries demonstrated high level of safety and encouraging continuation rates of IUDs in young women [25–27]. However, as several new important articles on this topic have been published in the recent past, this review aims to provide a broad look at levonorgestrel-releasing intrauterine system (LNG-IUS) outcomes in the population of nulliparous women, regardless of their age.

In summary, as concerns about the use of LNG-IUS in nulliparous women may still limit the its availability in a large group of patients, an up-to-date overview on the available evidence is needed. Therefore, the objective of this systematic review was to summarize and critically appraise the available evidence about the use of LNG-IUS as a contraceptive method in nulliparous women.

2. Material and Methods

The protocol for this systematic review was registered at PROSPERO—an International Prospective Register of Systematic Reviews (CRD42019139169), and may be accessed at https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=139169.

The inclusion and exclusion criteria are summarized in Table 1.

Papers regarding the insertion procedure itself or pain perception and management were not considered, since major systematic reviews on the topics have been published by other authors in recent years [22–24].
Table 1. The inclusion and exclusion criteria.

| Inclusion Criteria | Exclusion Criteria |
|--------------------|--------------------|
| Study Status        | Completed, Published| Unfinished, Unpublished |
| Study Type          | RCT, non-RCT, cohort study, case-control study, case-control study, reviews, case reports, case series, letters to the editor, expert opinions, conference papers |
| Language            | English, Other than English |
| Year Published      | ≥1990, <1990 |
| Insertion           | In scheduled mode, As an emergency contraception or immediately after intervention/surgery f.e. abortion |
| Topic               | LNG-IUS as a long-term contraceptive method, LNG-IUS as a treatment f.e. of heavy menstrual bleeding |

Abbreviations: f.e.: for example; LNG-IUS: levonorgestrel-releasing intrauterine system; RCT: randomized controlled trial.

The following LNG-IUS outcomes were taken into account: efficacy (the rate of unintended pregnancies and Pearl Index (PI)), safety (the rate and kind of side effects), bleeding pattern, satisfaction (various satisfaction rates) and continuation (the rate of continuation and reasons for discontinuation). PI was defined as the number of pregnancies that occurred divided by the number of treatment cycles multiplied by 1300 times [28].

Four electronic databases were searched: MEDLINE (through PubMed), Scopus, Embase and CENTRAL. The search strategy for each database are presented in Table S1. The last search was run on 27th March 2020 on each database. We also reviewed the reference lists of selected studies, however, no additional records meeting the inclusion criteria were noted. It was not necessary to contact the authors of retrieved research articles for additional information.

A systematic literature search retrieved 816 studies. Duplicates were removed using the automatic EndNote X9 (Clarivate Analytics, Philadelphia, Pennsylvania, United States) duplicate finder, followed by a manual search. Titles and abstracts of remaining articles were independently screened by three study authors. Full-text versions of studies potentially eligible were assessed by three other authors. Details regarding the selection process are summarized in a custom-built PRISMA flow chart in Figure S1. In the next step, authors collected the baseline characteristics of the participants and outcomes for each selected study using a self-developed data extraction sheet. Any disagreements were resolved through discussion and consensus.

The risk of bias for the interpretation of the data on the use of LNG-IUS in nulliparous in the selected studies was analyzed with the use the Newcastle-Ottawa Quality Assessment Scale, modified by the authors for the needs of this review [29] (Table S2). A study was awarded one star each star-rated feature within the Selection and Outcome categories. A maximum of two stars could be awarded for Comparability. Finally, a study was rated as having a low risk of bias if it gained: 3 or 4 stars in “Selection” AND 1 or 2 stars in “Comparability” AND 2 or 3 stars in “Outcome”; moderate risk of bias if: 2 stars in “Selection” AND 1 or 2 stars in “Comparability” AND 2 or 3 stars in “Outcome”; high risk of bias if: 0 or 1 star in “Selection” OR 0 stars in “Comparability” OR 0 or 1 stars in “Outcome”.

3. Results

As a result of the described search procedure, 23 articles that meet all the inclusion criteria were retrieved [30–52]. Basic data on the research works included in this systematic review are collected in Table 2.
Table 2. Characteristics of the studies included in the systematic review.

| Authors & Year | Type of the Study | Main Aim | Population of Nulliparous LNG-IUS Users | Type of LNG-IUS | Observation/ Follow-Up Time |
|----------------|-------------------|----------|----------------------------------------|----------------|-----------------------------|
| Pakarinen et al. 1996 [41] | Randomized prospective | To compare the efficacy, safety and acceptability of LNG-IUS situated in the cervical canal or uterine cavity | N = 145 69 LNG-IUS intracervical 76 LNG-IUS intrauterine | Mirena 20 µg/24 h | 1 year |
| Suhonen et al. 2004 [45] | Randomized prospective | To compare the safety and acceptability of LNG-IUS and OCs in young nulliparous women | N = 94 Median age: 21; Range: 18-25 | Mirena 20 µg/24 h; Total content: 52 mg; Size: 32 x 32 mm | 1 year |
| Wildemeersch et al. 2005 [51] | Open prospective noncomparative | To evaluate the ease of insertion, contraceptive performance and the safety of LNG-IUS Femilis | N = 92 Mean age: 29; Range: 16-50 | Femilis 20 µg/24 h; Total content: 40 mg; Size: 30 x 24 mm | 1 year |
| Römer et al. 2009 [42] | Cross-sectional | To identify the characteristics and experiences of women using LNG-IUS | ~ 694 8% of 8680-whole study group | Mirena 20 µg/24 h; Total content: 60 mg; Size: 32 x 32 mm | 5 years |
| Wildemeersch et al. 2009 UPDATE ON: Wildemeersch et al. 2005 [50] | Open prospective noncomparative | To provide an update on the performance of LNG-IUS Femilis in parous and nulliparous women | N = 112 Mean age: 29; Range: 17-48 | Femilis 20 µg/24 h; Total content: 60 mg; Size: 30 x 28 mm | 20% used IUS < 1 year, 16% 1–2 years, 15% 2–3 years, 14% 3–4 years, 13% 4–5 years, 18% > 5 years, 3% no data |
| Bahamondes et al. 2011 [32] | Retrospective cohort | To evaluate the ease of insertion and clinical performance of LNG-IUS in nulligravidas for up to 1 year after insertion | N = 158 Mean age: 30 | Mirena 20 µg/24 h; Total content: 52 mg; Size: 32 x 32 mm | 1 year |
| Marions et al. 2011 [39] | Non-interventional cohort | To gain knowledge about the insertion and the use of LNG-IUS in nulliparous women | N = 224 Median age: 20 | Mirena 20 µg/24 h; Total content: 52 mg; Size: 32 x 32 mm | Follow-ups: 1st 2–5 weeks (N = 137) 2nd 12–26 weeks (N = 197) 3rd 30–124 weeks (optional) (N = 134) |
| Armitage et al. 2013 [31] | Observational prospective | To follow 100 women attending for fitting LNG-IUS at a single urban general practice serving students | N = 97 Age range: 18–38 | Mirena 20 µg/24 h; Total content: 52 mg; Size: 32 x 32 mm | 1 year |
| Madden et al. 2014 [38] Secondary analysis of Contraceptive CHOICE Project [53] | To investigate if young age and nulliparity were associated with the expulsion of LNG or Cu-IUS | N = 1690 | Mirena 20 µg/24 h; Total content: 52 mg; Size: 32 x 32 mm | 1 year |
| Authors & Year             | Type of the Study | Main Aim                                                                 | Population of Nulliparous LNG-IUS Users | Type of LNG-IUS | Observation/ Follow-Up Time |
|---------------------------|-------------------|--------------------------------------------------------------------------|-----------------------------------------|-----------------|------------------------------|
| Savasi et al. 2014 [43]  | Retrospective     | To assess complication rates with the use of LNG-IUS in adolescents with developmental disabilities | N = 54                                   | Mirena 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | Follow-up after the insertion of IUD ranged from 0 to 51 months (15 months on average) |
| Zhao et al. 2014 [52]    | Prospective       | To analyze experiences and the levels of satisfaction with Mirena among Chinese women | N = 77                                   | Mirena 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | Follow ups: 1st 3–4 months 2nd 1 year |
| Abraham et al. 2015 [30] | Secondary analysis of Contraceptive CHOICE Project [53] | To assess the relationship among young age, nulliparity and the continuation of LARC methods | N = 1456                                  | Not specified   | Follow ups: 1st 1 year 2nd 2 years |
| Kaislasuo et al. 2015 [37]| Prospective cohort | To assess if small uterine cavity size was associated with bleeding problems or pain in nulligravid women using IUD | N = 111                                   | Mirena 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | 1 year |
| Gemzell-Danielsson et al. 2015 [35]| Randomized prospective | To evaluate if the outcomes of LNG-IUS were affected by parity, age or BMI | N = 1130 Age range: 18–35 | 49%-LNG-IUS 8 µg/24 h Total content: 13.5 mg 51%-LNG-IUS 13 µg/24 h Total content: 19.5 mg Both size: 28 × 30 mm | 3 years |
| Eisenberg et al. 2015 [34]| Partially randomized prospective | To assess 3-year data on the efficacy and safety of 52 mg LNG-IUS | N = 1011 at enrollment Mean age: 25 Range: 16–45 | Lilletta 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | 3 years |
| Mejia et al. 2016 [40]   | Secondary analysis of Contraceptive CHOICE Project [53] | To evaluate the effect of baseline bleeding patterns on the rates of amenorrhea during the use of 52 mg LNG-IUS | N = 515                                     | Mirena 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | 1 year |
| Hall et al. 2016 [36]    | Observational     | To follow college students who chose IUD and assess the insertion, use, continuation, and satisfaction | N = 88 Aged 18–30 | Mirena 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | 1 year |
| Wildemeersch et al. 2017 [49]| Observational prospective | To report on the contraceptive performance of LNG-IUS after 5 years of use | N = 117 Mean age: 27 Range: 15–47 | Femilis 20 µg/24 h Total content: 60 mg Size: 30 × 28 mm | 5 years (N = 114) |
### Table 2. Cont.

| Authors & Year | Type of the Study | Main Aim | Population of Nulliparous LNG-IUS Users | Type of LNG-IUS | Observation/ Follow-Up Time |
|----------------|-------------------|----------|----------------------------------------|----------------|-----------------------------|
| Darney et al. 2018 [33] | Prospective cohort | To evaluate amenorrhea rates and predictors during the 1st year of LNG-IUS use | $N = 822$ | Liletta 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | 1 year |
| Schreiber et al. 2018 [44] | Prospective | To evaluate bleeding patterns for Liletta using the WHO Belsey definitions | $N = 982$ | Liletta 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | First 90 days ($N = 982$) Second 90 days ($N = 949$) Last 90 days of year 1 ($N = 866$) Last 90 days of year 2 ($N = 711$) Last 90 days of year 3 ($N = 568$) |
| Vaitsiakhovich et al. 2018 [48] | Cross design analysis of randomized and observational data | To evaluate the discontinuation rate of LNG-IUS in real-life setting | $N = 50$ | Mirena 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | 2 years |
| Teal et al. 2019 UPDATE ON: Eisenberg et al. 2015 [46] | Partially randomized prospective | To re-assess the efficacy and safety of 52 mg LNG-IUS after 5 years of use (the continuation of Eisenberg et al. 2015) | $N = 1011$ Mean age: 25 Range: 16–45 | Liletta 20 µg/24 h Total content: 52 mg Size: 32 × 32 mm | 5 years ($N = 986$) |
| Teunissen et al. 2019 [47] | Retrospective cohort | To investigate differences in continuation rates between the contraceptive and therapeutic use of LNG-IUS | $N = 379$ | Total content: 52 mg | Minimum 5 years |

Abbreviations: BMI: body mass index; Cu-IUS: Copper-releasing intrauterine system; IUS: intrauterine system; LNG-IUS: levonorgestrel releasing intrauterine system; OC: oral contraceptives; WHO: World Health Organization; LARC: long-acting reversible contraception; IUD: intrauterine devices.
In only one of the studies that met the previously assumed criteria, the study group consisted of patients using low-dose IUS [35]. Both LNG-IUS 8 µg/24 h and LNG-IUS 13 µg/24 h were proved by Gemzell-Danielsson et al. to be comparably highly effective, safe and gained with similar high satisfaction and continuation rates among users [35]. Nevertheless, it needs to be underlined that there are other studies on low-dose LNG-IUS usage in a mixed population—both parous and nulliparous women, in which their general safety and effectiveness were demonstrated, however, no separate calculations on this review outcomes of interest depending on the parity were reported [54–56]. The vast majority of available studies comparing the use of different types of IUS in a group of nulliparous women focus on the procedure of insertion and accompanying pain, which was the subject of other systematic reviews [22–24].

4. Discussion

4.1. Efficacy

A total of 12 out of 23 articles reported data on the pregnancy rates in groups of nulliparous LNG-IUS users [31,32,34–36,39,43,45,46,49–51]. Considering only those research papers in which the observation period was strictly defined, 11 pregnancies occurred in 9887 women-years of observation (based on eight studies: [31,32,35,36,45,46,49,51]). This amounts to a PI of about 0.11. However, it should be noted that it is uncertain whether women included in various studies used other methods of contraception simultaneously (e.g., barrier), or whether there were any other factors potentially distorting this indicator. The reported pregnancies were mostly ectopic—five out of seven in the study conducted by Gemzell-Danielsson et al. [35]. As regards the study by Teal et al. ectopic pregnancies accounted for 67% of all pregnancies in the study group (nulliparous and parous women analyzed jointly) [46].

4.2. Expulsion

A total of 14 out of 23 articles investigated the occurrence of expulsion in the analyzed population [31,32,34–39,41,43,45,46,49,51]. Using analogous calculations, 144 expulsions occurred during 11365 women-years (0.01 expulsion in 1 women-year; based on: [31,32,35–38,41,45,46,49,51]). Moreover, among six studies that compared expulsion indices depending on parity, five reported significantly lower numbers of expulsion in nulliparous than in the parous women [34,35,38,41,46], whereas Bahamondes et al. did not find a significant difference between groups [32]. Moreover, Madden et al. reported a decreased risk of LNG-IUS expulsion in nulliparous women (hazard ratio 0.59 (95% CI 0.44–0.78)). Interestingly, the authors also observed a doubled expulsion risk in females aged 14–19 compared to older women, but such a relationship is hard to explain [38]. However, the risk of expulsions remains low, and most cases may be recognized almost immediately, yet only unrecognized expulsions are considered clinically important [57].

4.3. Continuation

A total of 15 out of 23 articles reported data on the continuation rates in the studied population [30–32,35–37,39,41,43,45,47–49,51,52] (Table 3). In the studies assessing the rate of continuing treatment after the first year, continuation rates ranged from 73% (Kaislasuo et al.) up to 93% (Hall et al.). However, Kaislasuo et al. also considered 16% of lost to follow-up cases as a discontinuation [36,37]. For longer follow-ups, the rates were as follows: 3 years—50–58% [35,47]; 5 years—11–54% [47,49]. Apart from expulsion, the most common reasons for discontinuation in the retrieved studies were: bleeding, pain, will to conceive. Hall et al. reported that nulliparas using LNG-IUS had significantly higher continuation rates compared to those using Copper IUS (Cu-IUS) [36]. Similarly, Abraham et al. found that nulliparous women were more likely to discontinue Cu-IUS and implants than parous, but it was not reported for the group consisting of LNG-IUS users [30]. This finding was also confirmed by other authors [32,49,52]. In a study conducted by Teunissen et al., continuation rates in women
with parity ≥ 2 were noticeably higher than in nulliparous ones at all follow-up visits (first year—77% vs. 81%; second year—64% vs. 72%; third year—50% vs. 65%; fourth year—38% vs. 59%; fifth year—11% vs. 24%; authors did not specify the level of statistical significance for those differences) [47]. Similar results were obtained on the basis of a crossed-design synthesis of randomized controlled trials (RCT) and observational study performed by Vaitsakhovich et al.. The continuation rates for parous women were 90% and 81% after 1 and 2 years, and the respective values for nulliparas accounted for 73% and 68% [48]. Gemzell-Danielsson et al. found that, after the first year of use, the continuation rate was significantly higher in parous women. However, after 3 years, there were no differences according to parity [35]. An interesting relationship was also found by Kaislasuo et al., who reported a significant association between an increasing fundal uterine width and the risk of discontinuation due to pain [37].

### Table 3. Continuation rates and reasons for discontinuation.

| Authors & Year | Continuation Rate | Expulsion | Pain | Unacceptable Bleeding | Pregnancy | Other |
|----------------|-------------------|-----------|------|-----------------------|-----------|-------|
| Pakarinen et al. 1996 [41] | 86.9% at 1st year |           |      |                       |           |       |
| Suhonen et al. 2004 [45] | 79.8% at 1st year | 1.1%      | 6.4% | 2.1%                  | 4.2%      | Hormonal: 4.2% Other medical: 2.1% |
| Wildemeersch et al. 2005 [51] | 90.2% at 1st year | 1.1%      | 2.2% | 2.2%                  | 3.2%      | Other: 1.1% |
| Bahamondes et al. 2011 [32] | 92.0% at 1st year | 3.7%      | 1.5% | 2.4%                  |           | Other medical: 0.8% Lost to follow-up: 1.6% |
| Martons et al. 2011 [39] | 73.1% at 1st year | 3.0%      | 11.9%| 10.4%                 |           | Infection/cyst: 1.5% |
| Armitage et al. 2013 [31] | 77.3% at 1st year | 2.1%      | 4.1% | 2.1%                  |           | Lost to follow up: 10.3% Others: 4.1% |
| Zhao et al. 2014 [52] | 90.0% at 1st year |           |      |                       |           |       |
| Abraham et al. 2015 [30] | Younger than 20: 81.0% at 1st year | 67.0% at 2nd year | 20–25 years old: 87.0% at 1st year | 79.0% at 2nd year | Older than 25: 87.0% at 1st year | 77.0% at 2nd year |
| Kaislasuo et al. 2015 [37] | 73.0% at 1st year | 2.7%      |      | 1.8%                  |           | Other: 6.3% Lost to follow-up: 16.2% |
| Gemzell-Danielsson et al. 2015 [35] | LNG-IUS 8: 78.8% at 1st year | 54.3% at 2nd year | LNG-IUS 13: 79.9% at 1st year | 58.1% at 2nd year |
| Hall et al. 2016 [36] | 93.1% at 1st year | 1.4%      |      |                       |           | Side effects: 4.2% Lack of benefit: 1.4% |
| Wildemeersch et al. 2017 [49] | 53.8% at 5th year | 0%        | 6.0% | 29.9%                 |           | Other medical: 6.8% Lost to follow up: 2.6% Pregnancy: 0.9% |
| Vaitsakhovich et al. 2018 [48] | In RCT: 74.0% at 1st year | 70.0% at 2nd year |           |                       |           |       |
| Teunissen et al. 2019 [47] | 76.8% at 1st year | 63.6% at 2nd year | 30.4% at 3rd year | 37.5% at 4th year | 11.1% at 5th year |

Abbreviations: LNG-IUS: levonorgestrel-releasing intrauterine system; RCT: randomized controlled trial.
It is worth noting in this section that the number of patients continuing a contraceptive method to some extent reflects the degree of patient satisfaction and adjustment of the method to her needs. It may also provide information about her cooperation with the doctor [58]. Therefore, studies on nulliparous women involving in-depth analyses of discontinuation reasons—with and without the exclusion of patients who discontinued LNG-IUS only for will to conceive—might provide valuable information on this matter.

4.4. Bleeding Pattern

Bleeding profile disturbances are a rare yet probable scenario during LNG-IUS use, including among nulliparous women. The unacceptable bleeding pattern was one of the most common reason for LNG-IUS discontinuation, but still, such a situation occurred within a very small percentage of nulliparous users—from 2% during the first year of use, up to 6% during the fifth year of usage [31,32,49,51]. Nevertheless, bleeding pattern seems to be a crucial aspect of contraception for women, since Marions et al. reported that the level of satisfaction was dependent on the frequency and volume of bleeding and dysmenorrhea [39]. Several authors obtained similar amenorrhea rates in nulliparous LNG-IUS users—from 18% to 26% at the end of the first year of use, and even up to 36% at the end of the third year in the study by Schreiber et al. [33,35–37,39,40,44,45]. Moreover, the latter found that: infrequent bleeding rate increased from 12% to 30%, frequent bleeding rate decreased from 29% to 4%, prolonged bleeding rate decreased from 50% to 2% and irregular bleeding rate decreased from 39% to 4% during the last 90 days of the second year, in comparison to the first 90 days of usage. The bleeding patterns did not vary between parous and nulliparous women. Darney et al. also found no significant differences in the percentage of amenorrhea between parities [33]. Other authors also reported a decrease in the percentage of dysmenorrhea, spotting and irregular bleeding over time [39,45]. Suhonen et al., who aimed to compare LNG-IUS and oral contraceptives (OCs) in young nulliparous women, found that the use of LNG-IUS resulted in a more effective alleviation of dysmenorrhea, and a decreased amount of blood loss and bleeding days, than with OCs [45]. Kaislasuo et al. reported a relation between uterine cavity size and the bleeding pattern—decreasing uterine cavity size correlated with fewer spotting days and fewer days of pain. Moreover, baseline scanty menstrual bleeding predicted amenorrhea at 10–12 months (OR 8.17 (95% CI 1.38–48.21)), and so did smoking (OR 8.23 (95% CI 1.76–38.56)) [37]. Gemzell-Danielsson et al. studied the satisfaction of nulliparous users with bleeding pattern during the use of LNG-IUS—up to 73% of eight LNG-IUS users and 71% of 13 LNG-IUS users stated that they were ‘very satisfied’ or ‘somewhat satisfied’ with their menstrual bleeding pattern [35].

4.5. Other Side Effects

Among the retrieved articles, only one partial perforation, a case of myometrial embedment, was reported by the authors of the studies [35]. Moreover, Hall et al. reported one case of endometritis [36]. Apart from Gemzell-Danielsson et al., who calculated the crude rate of pelvic inflammatory disease (PID) over up to 3 years at 1% [35], other authors did not report this or any other serious side effects. A broader analysis of mild side effects was carried out by Suhonen et al., who compared the occurrence of selected symptoms at baseline and after 1 year of LNG-IUS use. They reported an increase in abdominal/back pain (34% vs. 55%), headache (56% vs. 60%), acne (39% vs. 59%), breast tenderness (33% vs. 37%), mood swings (52% vs. 57%), a stable percentage of depressive mood (45% for both assessment periods) and a decrease in irritability (58% vs. 52%). In contrast to subjectively experienced edema and weight gain in the LNG IUS group, no statistically significant increase in weight was noted [45].

There is still relatively little data in the available literature regarding the long-term safety of IUD use, especially regarding fertility. Nevertheless, those available do not indicate an increased risk of infertility [59,60].
4.6. Satisfaction

Only five out of 23 studies reported on the satisfaction with contraception method in nulliparous LNG-IUS users, and the rates ranged from 76% to 96% [35,39,42,45,52], with most studies reporting satisfaction in above 90% of participants (data summarized in Table 4).

| Authors & Year | Assessment Time | Satisfaction Rate | Other |
|----------------|-----------------|-------------------|-------|
| Suhonen et al. 2004 [45] | 1st year | 90% ‘moderately’ to ‘very good’ | 88% would like to continue |
| Römer et al. 2009 [42] | Various | 93% ‘rather satisfied’ (31%) to ‘very satisfied’ (62%) at various times | 86% would recommend to a friend; 87% would like to continue |
| Marions et al. 2011 [39] | 12-16 weeks | 76% ‘very satisfied’ or ‘satisfied’; 10% ‘neither satisfied or dissatisfied’; 6% ‘dissatisfied’ | 5% data missing |
| Zhao et al. 2014 [52] | 3–4 months 1st year | 92% ‘very satisfied’ or ‘rather satisfied’ | 85% ‘very satisfied’ or ‘rather satisfied’ |
| Gemzell-Danielsson et al. 2015 [35] | 3rd year | LNG-IUS 8-94% ‘very satisfied’ or ‘somewhat satisfied’ LNG-IUS 13-96% ‘very satisfied’ or ‘somewhat satisfied’ | LNG-IUS 8-93% would like to continue LNG-IUS 13-80% would like to continue |

Abbreviations: LNG-IUS: levonorgestrel-releasing intrauterine system.

It is worth mentioning that Suhonen et al. reported that significantly more LNG-IUS users wanted to continue the method after the study than in case of OC group (88% vs. 68%) [45]. Marions et al. also noted that the satisfaction rate was better in the youngest age group (≤ 20 years) than in the oldest studied group (≥ 31 years; 75% and 59%, respectively) [39].

4.7. Limitations and Strengths

The greatest advantage of this review is the fact that it contains the most up-to-date and extensive summary of the available data on the use of LNG-IUS in nulliparous women. Conversely, one of the biggest limitations is the paucity of quantitative analyses. This is due to the fact that the individual studies mostly used different methods to assess the various aspects of LNG-IUS use. Another noteworthy aspect is the problem with the nomenclature and different inclusion criteria of nulliparous or nulligravidas women in analyzed studies. Very few studies have defined this population in detail, e.g., by reporting the percentage of women who have undergone early pregnancy termination, which may be the source of some bias. Regrettably, not all reported basic outcomes, e.g., about the occurrence of unwanted pregnancies or perforations. In addition, the studies differed from basic characteristics of the population to the type of LNG-IUS applied. The vast majority of them investigated Mirena or other comparable in levonorgestrel dose and size IUS, which did not allow us to analyze the impact of these factors on outcomes of interest. What is more, in the generally available literature, there are still very few studies directly comparing different types of IUDs, which might be particularly important from a clinical point of view [54]. Nevertheless, some researchers attempt to analyze the purposefulness of adjusting the type of LNG-IUS to individual patients. For example, Wildemeersch et al.—who examined the uterine cavity size in over 400 nulliparous women seeking IUD insertion, and came to the conclusion that the vast majority of them have too narrow a uterine cavity to fit conventional IUD (32 mm)—suggested that smaller inserts might potentially be more appropriate in this group [61]. The risk of bias analysis indicated that, in terms of data on the usage of LNG-IUS in nulliparous women, most of the studies included in the review showed low bias risk (N = 12, 52%). Nevertheless, the remaining 11 studies was characterized by moderate or high bias risk (N = 2 (9%) and N = 9 (39%) respectively). Most of them rated low in the Comparability section, mainly due to the fact that nulliparous population has not been minutely characterized, which may potentially be the source of some bias. For details of the assessment see Table S2.
5. Conclusions

The review indicates that LNG-IUS is an effective and safe contraceptive method for nulliparous women, which also achieves high levels of satisfaction among patients. In addition, nulliparous women seem to experience fewer expulsions than parous ones. Bleeding pattern is acceptable for the majority of patients, and any bleeding profile disorders mainly occur in the first months after the insertion. Further in-depth, long-term prospective studies on different types of LNG-IUS in size and dosage are necessary in this patient group, to determine risk factors for the occurrence of side effects and associated discontinuations, which should not, however, delay the wider use of the method in this group, given the number of advantages and relatively few disadvantages.

Supplementary Materials: The following are available online at http://www.mdpi.com/2077-0383/9/7/2101/s1, Figure S1. PRISMA 2009 Flow Diagram, Table S1. The search methods for used databases, Table S2. Risk of bias assessment.

Author Contributions: Conceptualization, M.Z., I.S., M.C., K.K.-K.; Methodology, M.Z., M.C.; Investigation, M.Z., K.K., I.S., M.M.D.-W., M.C., K.K.-K.; Resources, M.Z., K.K., I.S., M.M.D.-W., M.C., K.K.-K. (abstracts screening: M.Z., K.K., M.M.D.-W.; full-text screening: I.S., M.C., K.K.-K.; data collection: M.Z., M.C., K.K.); Data curation, M.Z., K.K., M.C., K.K.-K.; Risk of bias assessment: M.Z.; Writing—original draft preparation, M.Z., K.K., I.S., K.K.-K., M.M.D.-W., M.C., K.K.-K.; Writing—review and editing, M.Z., K.K., I.S., M.M.D.-W., M.C., K.K.-K.; visualization, M.Z., K.K., M.C.; Supervision, K.K.-K., I.S., M.C.; Project administration, M.Z., M.C.; Funding acquisition, K.K.-K., M.C. All authors actively participated in creating article text and have read and agreed to the published version of the manuscript.

Funding: This study was funded by The Centre of Postgraduate Medical Education. Grant number: 501-1-022-26-20.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References
1. Higgins, J.A.; Smith, N.K. The Sexual Acceptability of Contraception: Reviewing the Literature and Building a New Concept. *J. Sex Res.* 2016, 53, 417–456. [CrossRef] [PubMed]
2. Sitruk-Ware, R.; Nath, A.; Mishell, D.R., Jr. Contraception technology: Past, present and future. *Contraception* 2013, 87, 319–330. [CrossRef] [PubMed]
3. Hubacher, D.; Trussell, J. A definition of modern contraceptive methods. *Contraception* 2015, 92, 420–421. [CrossRef] [PubMed]
4. Luukkainen, T. Levonorgestrel-releasing intrauterine device. *Ann. N. Y. Acad. Sci.* 1991, 626, 43–49. [CrossRef] [PubMed]
5. Winner, B.; Peipert, J.F.; Zhao, Q.; Buckel, C.; Madden, T.; Allsworth, J.E.; Secura, G.M. Effectiveness of long-acting reversible contraception. *N. Engl. J. Med.* 2012, 366, 1998–2007. [CrossRef]
6. Zgliczynska, M.; Szymusik, I.; Sierocinska, A.; Bajaka, A.; Rowniak, M.; Sochacki-Wojcicka, N.; Wielgos, M.; Kosinska-Kaczynska, K. ContraceptiveBehaviors in Polish Women Aged 18-35-a Cross-Sectional Study. *Int. J. Environ. Res. Public Health* 2019, 16, 2723. [CrossRef]
7. Black, A.; Guilmbert, E.; Co, A.; Costescu, D.; Dunn, S.; Fisher, W.; Kives, S.; Mirosh, M.; Norman, W.V.; Pymar, H.; et al. Canadian Contraception Consensus (Part 1 of 4). *J. Obstet. Gynaecol. Can.* 2015, 37, 936–942. [CrossRef]
8. Black, A.; Guilmbert, E.; Costescu, D.; Dunn, S.; Fisher, W.; Kives, S.; Mirosh, M.; Norman, W.; Pymar, H.; Reid, R.; et al. Canadian Contraception Consensus (Part 3 of 4): Chapter 7-Intrauterine Contraception. *J. Obstet. Gynaecol. Can.* 2016, 38, 182–222. [CrossRef]
9. Bahamondes, L.; Fernandes, A.; Monteiro, I.; Bahamondes, M.V. Long-acting reversible contraceptive (LARCs) methods. *Best Pract. Res. Clin. Obstet. Gynaecol.* 2019. [CrossRef]
10. Trussell, J. Contraceptive efficacy. In *Contraceptive Technology, Twentieth Revised Edition*; Hatcher, R., Trussell, J., Nelson, A., Cates, W., Kowal, D., Policar, M., Eds.; Ardent Media: New York, NY, USA, 2011.
11. Kailasam, C.; Cahill, D. Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system. *Patient Prefer. Adherence* 2008, 2, 293–302. [CrossRef]
12. Bahamondes, L.; Valeria Bahamondes, M.; Shulman, L.P. Non-contraceptive benefits of hormonal and intrauterine reversible contraceptive methods. Hum. Reprod. Update 2015, 21, 640–651. [CrossRef] [PubMed]

13. Committee on Practice Bulletins-Gynecology, Long. Practice Bulletin No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices. Obstet. Gynecol. 2017, 130, e251–e269. [CrossRef]

14. Kavanaugh, M.L.; Jerman, J.; Finer, L.B. Changes in Use of Long-Acting Reversible Contraceptive Methods among U.S. Women, 2009–2012. Obstet. Gynecol. 2015, 126, 917–927. [CrossRef] [PubMed]

15. Lohr, P.A.; Lyus, R.; Prager, S. Use of intrauterine devices in nulliparous women. Contraception 2017, 95, 529–537. [CrossRef] [PubMed]

16. Kavanaugh, M.L.; Frohwirth, L.; Jerman, J.; Popkin, R.; Ethier, K. Long-acting reversible contraception for adolescents and young adults: Patient and provider perspectives. J. Pediatr. Adolesc. Gynecol. 2013, 26, 86–95. [CrossRef]

17. Madden, T.; Allsworth, J.E.; Hladky, K.J.; Secura, G.M.; Peipert, J.F. Intrauterine contraception in Saint Louis: A survey of obstetrician and gynecologists’ knowledge and attitudes. Contraception 2010, 81, 112–116. [CrossRef]

18. Luchowski, A.T.; Anderson, B.L.; Power, M.L.; Raglan, G.B.; Espey, E.; Schulkin, J. Obstetrician-gynecologists and contraception: Practice and opinions about the use of IUDs in nulliparous women, adolescents and other patient populations. Contraception 2014, 89, 572–577. [CrossRef]

19. Fleming, K.L.; Sokoloff, A.; Raine, T.R. Attitudes and beliefs about the intrauterine device among teenagers and young women. Contraception 2010, 82, 178–182. [CrossRef]

20. Whitaker, A.K.; Johnson, L.M.; Harwood, B.; Chiappetta, L.; Creinin, M.D.; Gold, M.A. Adolescent and young adult women’s knowledge of and attitudes toward the intrauterine device. Contraception 2008, 78, 211–217. [CrossRef]

21. Mestad, R.; Secura, G.; Allsworth, J.E.; Madden, T.; Zhao, Q.; Peipert, J.F. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011, 84, 493–498. [CrossRef]

22. Zapata, L.B.; Jatlaoui, T.C.; Marchbanks, P.A.; Curtis, K.M. Medications to ease intrauterine device insertion: A systematic review. Contraception 2016, 94, 739–759. [CrossRef] [PubMed]

23. Anthoulakis, C.; Iordanidou, E.; Vatopoulou, A. Pain Perception during Levonorgestrel-releasing Intrauterine System Insertion in Nulliparous Women: A Systematic Review. J. Pediatr. Adolesc. Gynecol. 2018, 31, 549–556. [CrossRef] [PubMed]

24. Foran, T.; Butcher, B.E.; Kovacs, G.; Bateson, D.; O’Connor, V. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: A systematic review. Eur. J. Contracept. Reprod. Health Care 2018, 23, 379–386. [CrossRef] [PubMed]

25. Usinger, K.M.; Gola, S.B.; Weiss, M.; Smaldone, A. Intrauterine Contraception Continuation in Adolescents and Young Women: A Systematic Review. J. Pediatr. Adolesc. Gynecol. 2016, 29, 659–667. [CrossRef] [PubMed]

26. Diedrich, J.T.; Klein, D.A.; Peipert, J.F. Long-acting reversible contraception in adolescents: A systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017, 216, 364.e1–364.e12. [CrossRef]

27. Jatlaoui, T.C.; Riley, H.E.M.; Curtis, K.M. The safety of intrauterine devices among young women: A systematic review. Contraception 2017, 95, 17–39. [CrossRef]

28. Gerlinger, C.; Endrikit, J.; van der Meulen, E.A.; Dieben, T.O.; Dusterberg, B. Recommendation for confidence interval and sample size calculation for the Pearl Index. Eur. J. Contracept. Reprod. Health Care 2003, 8, 87–92. [CrossRef]

29. Wells, G.A.; DO’Connell, B.S.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 15 November 2019).

30. Abraham, M.; Zhao, Q.; Peipert, J.F. Young age, nulliparity, and continuation of long-acting reversible contraceptive methods. Obstet. Gynecol. 2015, 126, 823–829. [CrossRef]

31. Armitage, C.M.; Mitchell, C.; Wigan, C.; Smith, D.A. Uptake and continuation rates of the intrauterine system in a university student general practice population in the UK. J. Fam. Plan. Reprod. Health Care 2013, 39, 186–189. [CrossRef]

32. Bahamondes, M.V.; Hidalgo, M.M.; Bahamondes, L.; Monteiro, I. Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidas. Contraception 2011, 84, e11–e16. [CrossRef]
33. Darney, P.D.; Stuart, G.S.; Thomas, M.A.; Cwiak, C.; Olariu, A.; Creinin, M.D. Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use. *Contraception* 2018, 97, 210–214. [CrossRef] [PubMed]

34. Eisenberg, D.L.; Schreiber, C.A.; Turok, D.K.; Teal, S.B.; Westhoff, C.L.; Creinin, M.D. Three-year efficacy and safety of a new 52-mg levonorgestrel-releasing intrauterine system. *Contraception* 2015, 92, 10–16. [CrossRef] [PubMed]

35. Gemzell-Danielsson, K.; Apter, D.; Hauck, B.; Schmelter, T.; Rybowski, S.; Rosen, K.; Nelson, A. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial. *PLoS ONE* 2015, 10, e0135309. [CrossRef] [PubMed]

36. Hall, A.M.; Kutler, B.A. Intrauterine contraception in nulliparous women: A prospective survey. *J. Fam. Plan. Reprod. Health Care* 2016, 42, 36–42. [CrossRef]

37. Kaislasuo, J.; Heikinheimo, O.; Lähteenmäki, P.; Suhonen, S. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception. *Hum. Reprod.* 2015, 30, 1580–1588. [CrossRef]

38. Madden, T.; McNicholas, C.; Zhao, Q.; Secura, G.M.; Eisenberg, D.L.; Peipert, J.F. Association of age and parity with intrauterine device expulsion. *Obstet. Gynecol.* 2014, 124, 718–726. [CrossRef] [PubMed]

39. Marions, L.; Lövkvist, L.; Taube, A.; Johansson, M.; Dalvik, H.; Överlie, I. Use of the levonorgestrel releasing-intrauterine system in nulliparous women—A non-interventional study in Sweden. *Eur. J. Contracept. Reprod. Health Care* 2011, 16, 126–134. [CrossRef]

40. Mejía, M.; McNicholas, C.; Madden, T.; Peipert, J.F. Association of baseline bleeding pattern on amenorrhea with levonorgestrel intrauterine system use. *Contraception* 2016, 94, 556–560. [CrossRef]

41. Pakarinen, P.; Luukkainen, T.; Elomaa, K.; Ratsula, K.; Venesmaa, P.; Tuominen, J.; Lähteenmäki, P. A 12-month comparative clinical investigation of a levonorgestrel-releasing intracervical device situated in the uterine cavity or cervical canal. *Contraception* 1996, 54, 187–192. [CrossRef]

42. Römer, T.; Linsberger, D. User satisfaction with a levonorgestrel-releasing intrauterine system (LNG-IUS): Data from an international survey rmer and linsberger user satisfaction with the LNG-IUS. *Eur. J. Contracept. Reprod. Health Care* 2009, 14, 391–398. [CrossRef]

43. Savasi, I.; Jayasinghe, K.; Moore, P.; Jayasinghe, Y.; Grover, S.R. Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities. *J. Pediatr. Adolesc. Gynecol.* 2014, 27, 25–28. [CrossRef] [PubMed]

44. Schreiber, C.A.; Teal, S.B.; Blumenthal, P.D.; Keder, L.M.; Olariu, A.I.; Creinin, M.D. Bleeding patterns for the Liletta((R)) levonorgestrel 52 mg intrauterine system. *Eur. J. Contracept. Reprod. Health Care* 2018, 23, 116–120. [CrossRef] [PubMed]

45. Suhonen, S.; Haukkamaa, M.; Jakobsson, T.; Rauramo, I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: A comparative study. *Contraception* 2004, 69, 407–412. [CrossRef]

46. Teal, S.B.; Turok, D.K.; Chen, B.A.; Kimble, T.; Olariu, A.I.; Creinin, M.D. Five-Year Contraceptive Efficacy and Safety of a Levonorgestrel 52-mg Intrauterine System. *Obstet. Gynecol.* 2019, 133, 63–70. [CrossRef] [PubMed]

47. Teunissen, A.M.; Merry, A.H.H.; Devies, L.E.C.; Roumen, F.J.M.E. Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg. *Eur. J. Contracept. Reprod. Health Care* 2019, 24, 449–456. [CrossRef] [PubMed]

48. Vaitisliakhovich, T.; Filonenko, A.; Lynen, R.; Endrikat, J.; Gerlinger, C. Cross design analysis of randomized and observational data—Application to continuation rates for a contraceptive intra uterine device containing Levonorgestrel in adolescents and adults. *BMC Women Health* 2018, 18, 180. [CrossRef] [PubMed]

49. Wildemeersch, D.; Goldstuck, N.D.; Jackers, G. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS. *Gynecol. Endocrinol.* 2017, 33, 223–226. [CrossRef]

50. Wildemeersch, D.; Janssens, D.; Andrade, A. The Femilis LNG-IUS: Contraceptive performance-an interim analysis. *Eur. J. Contracept. Reprod. Health Care* 2009, 14, 103–110. [CrossRef]

51. Wildemeersch, D.; Janssens, D.; Vrijens, M.; Weyers, S. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems. *Contraception* 2005, 71, 465–469. [CrossRef]
52. Zhao, S.; Deng, J.; Wang, Y.; Bi, S.; Wang, X.; Qin, W.; Huang, Z.; Li, L.; Mi, X.; Han, L.; et al. Experience and levels of satisfaction with the levonorgestrel-releasing intrauterine system in China: A prospective multicenter survey. *Patient Prefer. Adherence* **2014**, *8*, 1449–1455. [CrossRef]

53. Secura, G.M.; Allsworth, J.E.; Madden, T.; Mullersman, J.L.; Peipert, J.F. The Contraceptive CHOICE Project: Reducing barriers to long-acting reversible contraception. *Am. J. Obstet. Gynecol.* **2010**, *203*, e1–115.e7. [CrossRef] [PubMed]

54. Nelson, A.; Apter, D.; Hauck, B.; Schmelter, T.; Rybowski, S.; Rosen, K.; Gemzell-Danielsson, K. Two low-dose levonorgestrel intrauterine contraceptive systems: A randomized controlled trial. *Obstet. Gynecol.* **2013**, *122*, 1205–1213. [CrossRef] [PubMed]

55. Gemzell-Danielsson, K.; Apter, D.; Dermout, S.; Faustmann, T.; Rosen, K.; Schmelter, T.; Merz, M.; Nelson, A. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2017**, *210*, 22–28. [CrossRef] [PubMed]

56. Gemzell-Danielsson, K.; Schellschmidt, I.; Apter, D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. *Fertil. Steril.* **2012**, *97*, 616–622.e3. [CrossRef]

57. Blumenthal, P.D.; Lerma, K. Intrauterine Device Expulsion after Postpartum Placement: A Systematic Review and Meta-Analysis. *Obstet. Gynecol.* **2019**, *133*, 582. [CrossRef]

58. Halpern, V.; Lopez, L.M.; Grimes, D.A.; Stockton, L.L.; Gallo, M.F. Strategies to improve adherence and acceptability of hormonal methods of contraception. *Cochrane Database Syst. Rev.* **2013**. [CrossRef]

59. Carr, B.R.; Thomas, M.A.; Gangestad, A.; Eisenberg, D.L.; Olariu, A.I.; Creinin, M.D. Return of fertility in nulliparous and parous women after levonorgestrel 52 mg intrauterine system discontinuation. *Fertil. Steril.* **2018**, *110*, e46. [CrossRef]

60. Stoddard, A.M.; Xu, H.; Madden, T.; Allsworth, J.E.; Peipert, J.F. Fertility after intrauterine device removal: A pilot study. *Eur. J. Contracept. Reprod. Health Care* **2015**, *20*, 223–230. [CrossRef]

61. Wildemeersch, D.; Hasskamp, T.; Nolte, K.; Jandi, S.; Pett, A.; Linden, S.; van Santen, M.; Julen, O. A multicenter study assessing uterine cavity width in over 400 nulliparous women seeking IUD insertion using 2D and 3D sonography. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2016**, *206*, 232–238. [CrossRef]